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Abstract
Leprosy is a granulomatous, chronic infection caused by Mycobacterium leprae that has been 
reported for than 2000 years. The infection primarily affects the skin and peripheral nerves. 
M. leprae is bacterium that cannot be cultured in vitro and transmission and pathophysi-
ological data is still uncertain and limited. Today the prevalence of this ancient disease is 
declining in most around the world. This decline is a direct effect of widespread adminis-
tration by public health workers of multidrug therapy. However, emerging despite the use 
of multidrug therapy, identifying and monitoring resistance are still necessary.
Keywords: leprosy, Hansen’s disease, epidemiology, clinical findings, multidrug 
treatment
1. Introduction
Leprosy is an ancient, granulomatous and chronic infection that caused by Mycobacterium lep-
rae. It primarily affects the skin and peripheral nerves and late diagnosis of the leprosy related 
with the various complications and disabilities. Clinical findings of leprosy based on the cellular 
immune response of the patient and the duration of the disease.
Diagnosis is made by clinical examination; however, it must be supported with laboratory to 
determine the classification and the treatment of the disease.
In leprosy, Multi Drug Therapy (MDT) has been recommended since 1982 as the standard treat-
ment. With MDT, relapse and the number of the new leprosy cases decreased. However, it is still 
important and necessary to closely monitorize the patients to prevent and eliminate the leprosy.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Epidemiology
According to data from the World Health Organization (WHO), there are 5.35 million leprosy 
patients in 1985, and this figure has declined to 210,758 in 2015 [1, 2]. The most probable 
cause of this decline in prevalence is the increasing public awareness, trainings made regard-
ing diagnosis and treatment after the worldwide determination of leprosy as a public health 
problem [3]. When the prevalence of leprosy is determined, the data of registered patients 
receiving MDT every year are used. While the state of the disease on the world is determined, 
aside from prevalence, new patient detection rates and grade-2 disabilities (G2D) definitions 
and new cases with visible deformities are also used by WHO [2].
In reducing of the prevalence of leprosy over a period of several years, in particular, reducing 
the treatment with dapsone for many years (4–10) to up to 1 year with MDT was effective 
[4, 5]. In contrast with the decline in prevalence, the new patient detection rate continued to 
increase until 2001. After 2001, the number of new diagnoses in parallel with the decrease in 
prevalence due to the early diagnosis and the success of MDT has decreased [5]. The health-
care infrastructure, which plays a very important role in detecting and controlling the disease, 
and the accessibility of health services directly affect these rates [6].
At the end of 2015, the prevalence was calculated to be 0.29 (174,608 cases) per 100,000 population, 
and the rate of new cases was calculated to be 3.2 (210,758 cases) per 100,000 population, accord-
ing to the number of patients receiving MDT in collected data by WHO from 138 countries [2]. 
Although the programs against leprosy are being prepared worldwide, currently, 14 countries, 
each reporting more than 1000 new patients per year, are generating 95% of newly diagnosed 
patients worldwide. In 2015, India alone accounts for 60% (127,326) of newly diagnosed patients, 
13% of Brazil (26,395) and 8% of Indonesia. The Democratic Republic of the Congo, Ethiopia, 
Madagascar, Mozambique, Nigeria, the United Republic of Tanzania, Bangladesh, Nepal, Sri 
Lanka, Myanmar and Philippines totally have a new patient detection rate of 14%. Although the 
rates vary in different countries, on average, 38.8% of the patients reported worldwide are woman 
and 8.9% of them are children. It is rare to have leprosy in infancy due to long incubation period [7].
The rate of G2D, which indicates identification of early signs and symptoms of leprosy and the 
response to treatment, is around 6.7% worldwide (1409 cases), indicating a delay in the detection 
of cases where this rate is still high [2]. The aim of the Global leprosy 2016–2020 is to reduce G2D 
ratio to less than 1 per 1 billion worldwide; and to withdraw the G2D ratio to zero in children [8].
2.1. Contamination
Despite the fact that leprosy is a very old disease, we still have a limited knowledge of contamina-
tion routes and reservoirs. Contamination usually occurs after prolonged contact with the nasal 
and oral secretions of lepromatous leprosy (LL) patients infected and untreated with M. leprae [9]. 
However, many cases have been reported supporting the possibility of transmission by different 
ways, and discussions on different ways of transmission are continuing. There are reports that 
leprosy cases reported to develop by tattooing and accidental needle penetration support that 
they can be transmitted through damaged skin, there are also reports supporting undamaged 
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skin contamination [10–13]. In addition, leprosy cases seen in the infant period also suggest a 
possible infection from mother via blood or with breast milk [7, 14, 15]. Numerous cases of lep-
rosy following direct or indirect contact, especially with nine-band armadillo, have been reported 
[16, 17]. In addition, a leprosy case developed after blood transfusion has been reported [18].
Bacillus M. leprae is showed by methods, e.g., skin biopsy, direct skin smear and electron micros-
copy; in different ratios in saliva, oral mucosa, hair follicle, hair shaft, sweat gland and canal, in 
the sebaceous gland orifice, in the mother’s milk, and very little in the placenta [13, 15, 19–24]. 
It should be kept in mind that leprosy, which still continues to be a public health problem, may 
have different modes of transmission.
2.2. Reservoir
Although M. leprae is thought to be a largely human-depended parasite for a very long time, 
there is so much evidence supporting a reservoir other than human [25]. According to recent 
data, there is no significant decrease in new case detection rates between 2010 and 2015, suggest-
ing that there may be reservoirs other than human [2]. The development of leprosy cases after 
direct or indirect contact with the nine-banded armodillo in the United States of America (USA) 
supports this idea [16, 17, 26]. In female chimpanzees brought from Africa to Japan for clinical 
trial purposes, development of leprosy after 30 years is important for the evidence regarding 
that leprosy may have both an incubation period and a non-human reservoir [27]. Findings also 
show that M. leprae is also present in environments such as insects, amoebae, soil, and water [25, 
28–31]. Considering that bacillus can survive for 46 days in moist environment and 60 days in 
water; even backwater may become the medium in which they can survive for a long time [32].
2.3. Incubation
Since there is no serological or biological method that may detect M. leprae in the latent phase, 
which is subclinic, it is not yet possible to identify exactly the duration of the incubation; but 
observational estimates can be made. The estimated average incubation period for multibacil-
lary leprosy (MB) is 5–10 years and sometimes more; for paucibacillary leprosy (PB), the aver-
age incubation period is 2–5 years [5].
2.4. Risk factors
2.4.1. Contact
In a case control study, when compared to the control group, those who had social contact 
and when compared to living in the same aquifer, those who are core households have a 
higher risk [33, 34].
2.4.2. Age
According to many specialist age is a risk factor and children below 14 years old who is in 
contact with MB patients as a householder are found to be at greater risk than adults [35–37]. 
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In addition, a study showing that bimodal distribution of risk for age has been shown that the 
risk increase ages 5–15 years and over 30 years.
2.4.3. Gender
Although there are a number of studies showing no significant difference between men and 
women, there is also a study reported that men are at greater risk [34–36].
2.4.4. Leprosy type and physical distance to the patient
Compared to the general population, sharing the same house with a leprosy patient increases 
the risk. Contact with MB leprosy patients is more risky when compared to contact with 
patients with PB single lesion leprosy, while the risk of contact with MB patients is similar to 
contact with PB leprosy patients with 2–5 lesions [34, 36, 38]. If there are two or more patients 
in the same house, the risk of contamination doubles [11].
2.4.5. BCG vaccine
For individuals in contact with the general population and leprosy patients, BCG vaccination 
administration at repeated doses provides protection against the leprosy [39–41]. Those who 
live in the same household and do not vaccinated with BCG vaccine are at greater risk [42].
2.4.6. Genetic distance
Studies have been carried out for years to clarify whether there is a relationship between lep-
rosy and genetics. Although not fully adequate, there are conclusions that support this idea. 
Moet et al. reported that genetic association is a risk factor predisposing to leprosy, regardless 
of physical distance [34]. Mire et al. found that the chromosome 6q25 locus was associated 
with leprosy susceptibility; Siddiqui et al. showed that the 10p13 locus was associated with PB 
leprosy [43]. There are also studies showing that HLA DR2 and non-HLA (SLC11A1, formerly 
NRAMP1 and TNF alpha) genes are also associated with leprosy [44, 45]. Genomic studies are 
important in combating leprosy in terms of having potential for improvement in treatment 
and vaccination. On the other hand, the presence of IL-17F (7488 t > C) single nucleotide 
polymorphism and the presence of IL-4 gene 4-590 T/C polymorphism are associated with 
decreased predisposition to leprosy [46, 47].
3. Microbiology and genetic
M. leprae is a compulsory intracellular organism, which is a fast-staining, very slow-growing 
(doubling time 14 days), which can reproduce at lower temperatures than body tempera-
ture [48]. Unlike other bacteria, it is thought that the reproduction pattern is not algorithmic. 
While the regions where it can reproduce in human body are at 25–33°C, whereas no M. leprae 
involvement is observed at 35–36°C regions [49].
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Reproduction of M. leprae in vitro conditions has not been fully successful until now and the 
reason for this is still unclear. Amako et al. reached results showing that M. leprae Thai-53 
strain grew in vitro in different media by digital droplet PCR method [50]. Most of the stud-
ies on the M. leprae have been carried out on armadillos. Low body temperatures (33–35°) of 
armadillos (Dasypus novemcinctus), long life cycles, and adequate body sizes have made them 
suitable hosts in experimental areas [26].
In 2001, by dissolving the genome sequence of M. leprae, new information about the disease 
has begun to be obtained [51]. M. leprae has the smallest genome among the mycobacteria 
species. M. leprae bacillus has undergone severe genomic disruption and diminution with 
reductive evolution [52]. Reductive evolution, especially in catabolism, has removed meta-
bolic pathways along with control pathways [53]. More than half of the genome consists of 
pseudogenes, inactive reading frames or regulating sequences. In addition, dominance of 
the bacillus genome has led to advances in topics such as molecular epidemiology, drug-
susceptibility testing, and understanding of the spread of the bacterium over the world [52].
4. Classification
Leprosy exhibits a broad spectrum of clinical and histopathological findings based on the cel-
lular immune response of the host. In 1966, Ridley and Jopling classified leprosy according to 
clinical and histopathologic features [54, 55]. According to this classification system there is a 
tuberculous form (TT) consisting of a strong immune response and a small number of microor-
ganisms at one end and a weak immunologic response and a lepromatous form (LL) overloading 
of microorganisms at the other end and three types of borderline leprosy; borderline tuberculoid 
leprosy (BT), mid-borderline (BB), borderline lepromatous leprosy (BL) between these two end. 
Conceptually, tuberculoid leprosy (TT) and lepromatous leprosy (LL) are clinically stable, while 
borderline forms may shift to stronger or weaker immunity.
In 1997, the WHO created a classification to provide leprosy treatment based on the number of 
lesions present, regardless of the size, localization, and histopathological features of the lesions, 
without laboratory support in endemic areas [56]. According to these, leprosy is divided to 3 sub-
group: single lesion leprosy, PB, 2–5 lesions and MB, more than 5 lesions. According to the WHO 
classification, BT may be considered in the PB, BB and BL may be considered in the MB spectrum.
5. Clinics
Clinical findings of leprosy are primarily due to skin and nervous system involvement. There 
are five common types of peripheral nerve changes:
1. Enlargement of peripheral nerves: Peripheral nerves are more frequently affected by super-
ficial placement. Unique findings such as anesthesia or hypoesthesia may develop as well 
as sensitivity and enlargement [55, 57]. Ulnar nerve in the elbow, median and superficial 
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radial cutaneous nerve in the wrist, large common auricular nerve in the neck, and com-
mon peroneal nerve enlargement in the popliteal fossa can be detected by palpation [57].
2. Presence of sensory defects such as anesthesia and hypoesthesia in skin lesions.
3. Sensory and motor function losses may occur depending on the location of nerves that 
are involved. General neurological examination was performed and neurological changes 
such as drop foot, flexion contracture 4–5 of the fingers, muscular atrophy, facial paralysis, 
and lagophthalmia may be detected [57].
4. Depending on the influence of thin, unmyelinated Type C fibers responsible for the trans-
mission of senses such as light touch, pain, hot, and cold; the sensory loss in the glove-
stocking pattern may be observed first in the hot-cold discrimination.
5. Anaphylaxis of palmoplantar area may be observed by the effected sympathetic nerve 
fibers.
Clinical forms of leprosy are determined according to clinical, bacteriological, immunological 
and histopathological criteria. According to that, leprosy has five clinical types:
5.1. Tuberculoid leprosy
It is a form of strong immune response that can be followed by spontaneous healing. Primary 
skin lesions are hairless, faintly elevated and endure, erythematous, squamous, annular plaques, 
which can be accompanied by neural involvements such as sharp anesthesia and hyperesthesia. 
The number of lesions is often solitary and does not exceed 10 cm in size. It can be seen as 
hypopigmented lesions in which partial pigment loss is observed, especially in dark-skinned 
individuals [54, 58]. Lesions should be examined thoroughly in terms of alopecia. Even if the 
enlargement and tenderness of the peripheral nerves near the cutaneous lesion are not detected, 
the lesion itself is typically hyperesthesia and anhidrotic [58].
5.2. Borderline tuberculoid leprosy
Although the immune response is sufficient to limit the disease, it is insufficient for spon-
taneous recovery [59]. Patients in this form may have a TT upgrade or borderline leprosy 
downgrade according to the change in the immunological response. Primary skin lesions are 
sharply defined, multiple, asymmetric, annular plaques and papules [54]. Lesions are less 
indurated and eleve, less erythematous, scarless, or slightly squamous than TT. The lesions 
can be seen in size to cover the entire limb. The lesions can be seen in size to cover the entire 
extremity. Loss of sense is observed in all lesions and nerve involvement (enlargement and 
paralysis) is usually asymmetry.
5.3. Mid-borderline leprosy
Immunologically, the two extremities are the midpoint of the spectrum [59]. The severity of 
cutaneous findings and neurological changes depend on which end of the patient is closer to. 
Primer skin lesions are generally asymmetric, alopecic, annular, sharply defined and broad 
platelets with the appearance of “Swiss cheese” where clinically normal skin islets are found.
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5.4. Borderline lepromatous leprosy
The immune system is weak enough to stop bacterial proliferation but sufficient to suppress 
inflammation that causes tissue damage [59]. Clinical findings are considerably diverse. 
Lepromatous lepra-like weak-edged and tuberculoid lepra-like sharp-edged plaques provid-
ing a classical dimorphic annular appearance are seen in only one of three patients [54]. Large 
plaques with sharp or weak edges and normal papules and nodules on which normal skin 
islands are visible can also be observed. The number of lesions varies from solitary to multiple. 
While the annular plaque lesions show asymmetrical placement, the nodules localized symmet-
rically. Neurological involvement is common and severe sensorimotor damage can be observed.
5.5. Lepromatous leprosy
Extensive disease is seen due to the inadequate cellular immune response. Classical lesions 
are characterized by multiple, diffuse, often symmetric, sharply defined papules, plaques and 
nodules. Involvement areas are usually the face, the hip and the lower extremity (Figure 1). 
The infiltration of the forehead skin leads to generation of lion face, which is a characteristic 
facial appearance (Figure 2). Hair loss is widespread, especially in the eyebrows (madarosis) 
and lashes [60].
Figure 1. Lower extremity involvement.
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Figure 2. Characteristic facial appearance (lion face).
6. Complications
Corneal dryness, abrasion and ulceration are very common in patients with leprosy due to 
the secretory irregularity and corneal insensitivity. A careful eye examination should be per-
formed in every leprosy patient to prevent serious complications that can result in blindness.
Depending on the perforation and collapse of the nasal septum, saddle nose and rhinitis-like 
findings can be observed. Snoring due to nodule occurrence in vocal cords and larynx involve-
ment, and gynecomastia, impotence and infertility as a result of decrease in blood testosterone 
level due to testicular involvement in male patients may be seen [61].
Venous insufficiency due to endothelial involvement of the valves of deep venous vessels may 
lead to stasis dermatitis and venous ulcers.
In the advanced disease phase, multiorgan involvement (liver, spleen, peripheral lymph nodes, 
bone marrow) can be observed.
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7. Immunologic reactions
Immunological reactions are inflammatory conditions that clinicians and patients may encoun-
ter before, during, or months or years after treatment [62]. Approximately 30–50% of patients are 
involved. There are two types of reactions that are linked to different immunological mechanisms 
that are not fully understood: Type 1 and type 2 [63]. These immunological reactions may mimic 
the drug reaction, the clinician should pay attention to that they are not drug reactions and that 
treatment should not be interrupted. In both types of reactions, general weakness, fatigue and 
fever can be observed. Other clinical findings differ according to the developing reaction.
Type 1 reaction: Typically occurs in TT and BT. It is due to an increase in cell-mediated immunity 
and a delayed-type hypersensitivity reaction to M. leprae antigens [55, 57, 63, 64]. Characteristic 
clinical findings are increased inflammation in existing lesions, formation of new lesions, pain 
and sensitivity in nerves (neuritis), progressive neurological failure.
Type 2 reaction: Typically, BL and LL patients develop when treatment begins. Pregnancy and 
pyogenic infections may induce. The type 2 reaction due to the formation of immune complex 
with hyper humoral immunity represents cutaneous and systemic small vessel vasculitis [55]. 
Characteristic clinical findings; painful nodular lesions (erythema nodosum leprosum) that 
occur suddenly, severe swelling and pain in the joints, iridocyclitis, orchitis, sensitive lymph-
adenopathy, glomerulonephritis, and hepatosplenomegaly [57, 63, 64].
Lucio phenomenon is a rare complication characterized by sudden-onset, necrotizing cutaneous 
small vessel vasculitis in diffuse, untreated LL patients in the Mexican and Caribbean region [65]. 
Lesions that are painful but have no increase in temperature can be cured by scarring. Ulceration 
especially may be observed in knees.
8. Differential diagnosis
Although reduction and absence of sensory perception distinguish leprosy lesions from other 
diseases, this finding may not always be detectable. With the reason that a wide variety of 
cutaneous lesions are present, leprosy can be confused with many diseases. In suspected 
patients, the exact diagnosis is made by skin biopsy.
Hypopigmented lesions may mimic pityriasis alba, pityriasis versicolor, mycosis fungoides 
and sarcoidosis [66].
Figured erythematous plaques may be confused with fungal infections, annular psoriasis, 
sarcoidosis, mycosis fungoides, lichen planus, systemic lupus erythematosus [66].
Infiltrated plaques and nodules generate definitive diagnosis with cutaneous leiomyoma, 
sarcoidosis, syphilis, keloid, cutaneous lymphoma, granuloma annulare [66].
In addition, definitive diagnosis of type 1 reaction includes acute lupus erythematosus, drug 
reactions, cellulitis; the definitive diagnosis of the type 2 reaction should be considered to 
include other conditions that may cause vasculitis and panniculitis.
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9. Diagnosis
For diagnosis, leprosy must first come to mind. Although diagnosis is made substantially by 
clinic examination, diagnosis must be supported by laboratory for classification and treat-
ment. Microbiological and pathological tests should be performed after history and clinical 
evaluation [67]. WHO recommends that individuals with one of the two cardinal findings in 
endemic regions are considered to be leprosy [68].
• Lesions compatible with leprosy with sensory loss (with or without nerve thickening).
• Positive skin smear.
Hypoesthesia skin lesion is the most important diagnostic factor because it is not expected 
in another skin disease other than leprosy. After evaluation of skin lesions, peripheral nerves 
should be palpated for thickening, and nerve examination of lesions and distal extremities 
should be performed [69]. Conjunctiva and corneal examination should also be made.
9.1. Sampling
Skin smear, a rapid diagnostic method, requires experience. The skin compressed between 
the thumb and index finger is cut with lancet with a width of 5 mm and a depth of 3 mm. 
The collected dermal fluid is spread on the lame. Tissue fluid should not be bloody. The most 
preferred regions are the earlobe, elbow and knee extensor faces. It may require three to six 
repetitions. The result is generally negative in less bacillar and TT. Nasal sampling is not 
recommended, especially because of fragility in LL cases. A 4 mm punch biopsy is the ideal 
method for sampling. The biopsy should be taken from the most erythematous, contagious 
and expanding area. Nerve biopsy may be required to support diagnosis, especially in cases 
of pure nerve involvement [67].
9.2. Microscopic examination
In vitro M. leprae culture is not possible. Demonstration of acid-resistant bacilli in material 
taken by skin smear or biopsy is standard diagnostic technique. With Ziehl-Neelsen staining, 
acid-resistant basils are colored fuchsia in blue background [67]. Bacteriological index (BI) is 
determined by rating between 1+ (1 bacteria in every 100 area) and 6+ (min. 1000 bacillus in 
every area) with the amount of bacteria in each microscope area. Patients with BI scores lower 
than 2 are considered as PB, whereas BI scores above 2 are considered MB [69].
9.2.1. Molecular methods
One of the molecular diagnostic methods, PCR, is the detection of M. leprae DNA. Biopsy 
material, tissue fluid, blood, urine, nerve tissue, oral and nasal mucosa swab and ocular lesions 
can be used for PCR [70]. While the specifity can be 100%, the sensitivity ranges from 34% 
to 80% in cases with PB forms to greater than 90% in cases with MB forms of the disease. 
The support of diagnosis is an important diagnostic tool in treatment follow-up, transmission 
surveillance of the immediate surroundings of leprosy individuals and in cases characterized 
with particularly pure nerve involvement which is difficult to diagnose or atypical lesions [71].
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9.2.2. Hystopathology
The main pathologic feature is a granulomatous reaction. Epithelioid cells, macrophages, 
lymphocytes, plasmocytes and rarely neutrophil and mast cells are observed. Different gran-
ulomatous reactions occur according to the immune response of the host. While epithelial 
cells are mostly observed in TT and BT cases, foamy macrophages are observed mostly in LL 
and BL cases.
• TL: The reaction is mostly multifocal, periadnexal and perineural. Infiltrate is in dermis. 
The epidermis is usually atrophic. Giant langerhans cells are pathognomonic. Multinuclear 
giant cells can be seen while plasma cells are not expected to be observed. Perineurium is 
intact and is surrounded by lymphocytes. It can even infiltrate with granuloma structures. 
There is marked edema in the nerve tissue.
• BT: Findings are similar to those for TT. Epithelioid cells are less maturated, giant cells 
are undifferentiated and small. Epithelioid granulomas are less organized and tubercular 
structures are less prominent.
• BB: Epithelioid cells are immature. Organized epithelial granuloma structures are absent. 
Lymphocyte spread is diffuse and macrophages are quite over. Nerve tissue is not edema-
tous. It has been infiltrated and partially destroyed by epithelial cells and lymphocytes.
• BL: Macrophage and lymphocyte predominant infiltration is present. Epithelioid cells are 
rare. Infiltration can be diffuse, nodular, perivascular and periadnexal. The epidermis and 
dermis are separated from each other by a narrow zone formed by the collagen. While 
macrophages contain more or less foamy cytoplasm, the formation of large vacuoles is not 
a feature of BL. The nerves have the onion skin perineurium.
• LL: The dermis is also characterized by diffuse macrophage invasion. There are no epithe-
lioid cells. The epidermis is atrophic and has a very apparent grenz zone. Skin attachments 
are surrounded by macrophages and are atrophic. Macrophages contain gray cytoplasm 
with foamy changes. Large vacuolarizations can be seen. Perineural macrophage accumula-
tion is present and perineum appears like onion skin. There is no sign of significant infiltra-
tion, and even the nerves can be quite normal. The nerves can be hyalinized or fibrotic [72].
9.2.3. Lepromin test
About 0.1 ml of lepromin antigen is administrated intradermally on to the forearm. The test 
is interpreted twice, first 24–48 hours and then 21 days. The first reaction is indicative of 
susceptibility, but may cross-react with other mycobacteria. The second reaction is resistance 
indicator to bacillus. Nodule >5 mm is considered positive. The most important point for 
the lepromin test is that it is not a diagnostic test, it should be used for classification and 
prognostic purposes.
9.3. Serology
M. leprae is stimulating cell-mediated abnormal response. Although the Ig that are formed 
are not protective, the importance of detection of the IgM formed towards PGL-1 (phenolic 
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glycolipid-1)-the only accessible test-is increasing day by day [67]. Search for effective diag-
nostic tests is accelerated by shifting the focus of the leprosy control strategy to early diag-
nostic and rapid treatment. Several studies have shown a correlation between serological 
titer and BI. The skin smear, the gold standard for classification, is thought to be a test that 
can be used as a support for clinical findings when histology is not possible [73, 74]. There 
was also a relationship between serology and reaction and relapse risk. Patients with a high 
PGL-1 Ig M level had a high risk of developing type 1 reactions [75]. In another study, post-
treatment reactions were found to be more likely to develop in patients with positive serology 
after treatment [76]. In another important meta-analysis, seropositive healthy contacts were 
observed to develop three times more leprosy when compared to negatives [77]. In the light 
of these findings; additional studies are needed to determine serology, classification, early 
diagnosis, follow-up of disease, detection of individuals at risk, and determination of who 
should take prophylaxis among these individuals.
10. Management
10.1. Medical treatment
MDT is the key point of disease control. Dapsone, rifampicin and clofazimine are the first 
line drugs. Because of the increased drug resistance due to monotherapy and the inef-
fectiveness of each one on M. leprae, the use of multiple drugs was initiated in 1981 in line 
with WHO’s recommendation. The use of dapsone, rifampin, and clofazimine (MB-MDT) 
is recommended for MB leprosy (BB, BL, LL), while dapsone and rifampin (PB-MDT) is 
recommended for TL, BT for 6 months since 1982. However, the duration of treatment 
for MB leprosy has changed over the years. The use of 12 months of MDT independent of 
smear is currently recommended, although formerly it was suggested that the treatment 
be continued until two consecutive negative skin smears are obtained [78, 79]. A single 
dose combination of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg is recom-
mended for patients with low baseline leprosy with a single lesion [80, 81]. Recommended 
doses are presented in Table 1.
Minocycline, clarithromycin and ofloxacin can be used as second-line drugs in MDT, where 
first-line drugs cannot be tolerated. Minocycline 100 mg/Daily can be used instead of dapsone 
and clofazimine, ofloxacin 400 mg/day instead of clofazimine, clarithromycin 500 mg/daily 
can be used where dapsone, clofazimine or rifampin cannot be tolerated [82].
WHO recommends that cases with a skin smear test +, or those without a definite diagnosis, 
are definitely treated with MB-MDT. Furthermore, attention should be paid to the fact that 
MB leprosy cases should not be treated with PB-MDT [81].
On the other hand, the National Hansen’s Disease Programs (NHDP)—in the USA—involves 
different regimen. Treatment is recommended 12 months for PB leprosy and 24 months for MB 
leprosy. Furthermore, unlike the current regimen of WHO, rifampin is used daily rather than 
monthly [82]. Recommended doses are presented in Table 1.
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WHO recommended treatment regimens NHDP recommended treatment regimens
Agent Dose Duration Agent Dose Duration
Tuberculoid (TT and BT)(paucibacillary) Tuberculoid (TT and BT) (paucibacillary)
Adult Dapsone 100 mg/daily 6 months Dapsone 100 mg/daily 12 months
Rifampicin 600 mg/a month Rifampicin 600 mg/daily
Childᵜ Dapsone 50 mg /daily Dapsone 1 mg/ kg/daily
Rifampicin 450 mg/a month Rifampicin 10–20 mg/kg/daily (not >600)
Lepromatous (LL, BL, BB) (multibacillary) Lepromatous (LL, BL, BB) (multibacillary)
Adult Dapsone 100 mg/daily 12 months Dapsone 100 mg /daily 24 months
Rifampicin 600 mg/a month Rifampicin 600 mg/daily
Clofazimine 50 mg/daily and 300 mg/a month Clofazimine 50 mg /daily
Childᵟ Dapsone 50 mg/ daily Dapsone 1 mg/kg/daily
Rifampicin 450 mg/a month Rifampicin 10–20 mg/kg/daily (not >600)
Clofazimine 50 mg/daily and 150 mg/a month Clofazimine 1 mg/kg/daily
ᵜAdjust dose appropriately for child less than 10 years. For example, dapsone 25 mg daily and rifampicin 300 mg given once a month under supervision.
ᵟAdjust dose appropriately for child less than 10 years. For example, dapsone 25 mg daily, rifampicin 300 mg given once a month under supervision, clofazimine, 50 mg 
given twice a week, and clofazimine 100 mg given once a month under supervision.
Table 1. Recommended treatment doses of leprosy.
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Moxifloxacin, pefloxacin, sparfloxacin, levofloxacin, and rifapentine that is a rifampin derivate 
are other agents with demonstrated efficacy [83, 84]. Clinical trials are needed in the long term.
Another treatment regimen studied is Uniform-MDT. It is the use for 6 months of dapsone, 
rifampin and clofazimine for patients with both PB and MB. However, the need for using 
additional clofazimine in PB patients and whether the treatment will be sufficient in MB 
patients are important questions present. This treatment is believed to set zero the risk of 
abduction of MB leprosy patients who received insufficient treatment by introducing a PB 
group [85]. In a study in which MB leprosy relapse was assessed in particular, relapse was 
found to be well below the targeted 5-year relapse rate of 5% [86]. Existing studies promises 
hope although further studies are needed [87, 88].
10.2. Treatment of immunological reactions
10.2.1. Type 1 reaction
Supportive therapies such as parol, non-steroidal anti-inflammatory drugs (NSAID), can be 
administered if there are no neuritis findings such as pain, function, or sensory loss. If nerve 
involvement is present, prednol 0.5–1 mg/kg/day peros is the first choice treatment. When the 
reaction is relieved, the dose is slowly reduced so that it remains above the dose of 0.25 mg/kg/day 
for at least 3–6 months. In ongoing process, dose reduction is continued with careful follow-up 
of nerve functions [89]. Cyclosporin is another option when steroids are not usable [90, 91]. In a 
study in which azothioprine was assessed, efficacy in type 1 reaction was not demonstrated [92].
10.2.2. Type 2 reaction
The incidence of type 2 reaction has decreased after addition of clofazimine to MDT with 
anti-inflammatory effect [93]. If there is no findings of neuritis, supportive treatment care such 
as NSAID (aspirin, indomethacin) and paracetamol may be administered. Prednol (0.5–1 mg/
kg/day) is the first choice if neuritis is present. Once the reaction is decreased, the dose should 
discontinued by reducing the dose in time. However, frequently the reaction relapse dur-
ing dose reduction. In this case, thalidomide, clofazimine and pentoxifylline can be used as 
adjuvants. WHO recommends to start by using clofazimine 3 * 100 mg (300 mg/day) and then 
reduces to 100 mg/day. It should not be used for type 2 reaction as a single agent and for more 
than 12 months. Reaction can be rapidly controlled by using thalidomide 300–400 mg/day. 
Dosage may be reduced to 100 mg/day for extended periods of usage. Since it is teratogenic, 
attention must be paid to the use in women who has childbearing potential [81]. Pentoxifylline 
is used as 3 * 400 mg. In a study that compares the efficacy of clofazimine and pentoxifylline, 
pentoxifylline effectively reduced the initial severity, while clofazimine showed a slow but 
sustained effect [94]. Resistant erythema nodosum leprosum cases that treated successfully 
with methotrexate, infliximab and etanercept have been reported [95–97].
11. Follow-up
WHO aims to follow the patients up monthly by 28-day drug supply. In regions where 
monthly follow-up is difficult, it is recommended that more than a monthly dose be given and 
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train family members or nearby people for observation purposes [81]. On the other hand, the 
NHDP recommends first follow-up on 1st month and then with 3 months periods. Reaction 
therapy should be followed up closely. Disease progression is largely due to incompatibility 
to treatment. Complete information about possible reactions, complications, drug side effects 
should be provided and the patient and his/her relatives compliance to treatment should 
be ensured. At each follow-up, laboratory tests for drug toxicity are recommended with full 
clinical evaluation including nerve examination. While complete blood, urea, creatinine, AST, 
ALT follow up is adequate, it is advisable to check glucose 6 phosphate dehydrogenase level 
for once for dapsone usage before treatment, if possible. A yearly skin smear or biopsy is 
recommended to follow the bacteria burden. After treatment, it is advisable to follow up at 
least 5 years of PB cases and 10 years of MB cases [82, 98].
Existence of persister strain, insufficient/inappropriate treatment, monotherapy, drug resis-
tance, high BI at diagnosis, number of lesions and lepromin negativity are factors that increase 
relapse risk. The risk of relapse after MDT has decreased considerably. In a study of 3248 patients 
followed for 16 years, cumulative relapse rates after MDT were 1.78% [99]. The relapse rate was 
6.1/1000 person years in one of the last current studies in which 2177 patients are followed up 
[100]. To reduce the risk of relapse, individualization of treatment duration is recommended in 
individuals predicted to be at high risk for relapse [101].
11.1. Drug resistance
Drug resistance is the result of leprosy-resistant transmission (primary resistance) or muta-
tion-induced secondary resistance which develops under treatment [102]. FolP1, rpoB, and 
gyrA gene mutations are associated with dapsone, rifampicin and ofloxacin resistance. Gene 
sequencing by PCR is a rapid and sensitive method to demonstrate drug resistance [103]. Due 
to the lack of effective second-line drugs; resistance to first-line drugs is a matter of concern 
to the WHO Global Leprosy Program. In 2008, drug resistance global surveillance was initi-
ated to assess the efficacy and drug resistance level of the current leprosy control strategy. 
Eighteen reference centers have been established in 18 pilot countries and mutation detection 
by PCR has begun. Obtained data suggest that resistant M. leprae does not pose a risk for cur-
rent disease management [104, 105].
12. Elimination/prevention
With MDT, in 1985, with 5.1 million leprosy cases falling to 3.1 million in 1991, WHO aimed 
to eliminate leprosy worldwide in 2000. Elimination target was 1/10,000. Countries like 
India and Brazil have been under the target even though the target has been reached sub-
stantially around the world. Although Brazil is one of the last countries to reach the goal 
today, endemic areas like Chhattisgarh, Pará and Madura are still far behind the target. 
On the other hand, in spite of successful elimination program, WHO declared in 2013 that 
leprosy control is faltered due to the plateau of the incidence of leprosy until 2005, the new 
diagnosis of leprosy cases with G2D remain constant between 2010 and 2013, and the num-
ber of new cases in children is not decreasing. In addition, late-diagnosis-related disability-
ending stigmatization of leprosy patients continued. Epidemiological data showed that the 
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prevalence-based elimination program could not stopped the spreading. The meeting was 
held in Brazil in 2015 and the strategy was changed. A strategy based on incidence instead of 
prevalence was identified. Early diagnosis and prompt inclusion of all patients to treatment 
were aimed [30, 106, 107].
Living in the same house with a leprosy person increases the risk of spreading by 2–10 fold. 
Most of the new cases constitute subclinical infection cases in contact and no diagnosed cases. 
For this reason, for eliminating leprosy, it is very important to detect new cases with effective 
contact monitoring. The development of diagnostic tests that can detect subclinical infection 
and separate exposure to and infection with M. leprae is very important [101, 108].
12.1. Immunoprophylaxis/chemoprophylaxis
In fact, BCG, which is tuberculosis specific, is the only vaccine used for leprosy protection. 
The level of protection, as well as the protection against leprosy is evidenced, varies between 
20% and 90% in the literature. Protection level of the vaccine, when vaccinated in first decade, 
was higher in women and lower socioeconomic individuals [109]. With age, the level of pro-
tection decreases [110]. Although it has been shown that revaccination of leprosy patients 
and contacts with them have been shown to reinforce the protection, this approach is still not 
common and there is a need for studies evaluating efficacy [39, 111].
Protection of post-contact chemoprophylaxis (PEP) has been shown in clinical trials in a range 
of 35–57% in patients with asymptomatic contact. Although it is not included in WHO’s 
official recommendations, PEP evaluations rapidly continue with a single dose of rifampin 
(SDR). One study has shown that the protection of PEP with BCG combination is better in 
distant-contact individuals [112]. With the cooperation of Novartis agency and Netherlands 
Leprosy Relief (NLR), Leprosy Post-Exposure Prophylaxis (LPEP) program has been estab-
lished. A large-scale study was started to investigate the applicability of the use of SDR as a 
PEP by the program and the impact on the number of new diagnosed cases. It is expected that 
the first data will be obtained in 2019 [113].
12.2. Prevention of disability
Permanent nerve damage is a part of the natural process of the disease, and the risk is also 
quite increased with leprosy reactions. Reducing the stigmatization of leprosy patients and 
providing mental well-being is possible by preventing nerve damage. Delay in recognition of 
leprosy and leprosy reactions, and therefore of delay in treatment is the most important factor 
on permanent nerve damage. Follow-ups should be done in leprosy centers whenever pos-
sible. It is important to ensure compliance with treatment and follow-up. Patients should be 
educated on issues such as care of existing wounds, proper shoe selection, self-examination 
of hands and feet. Another important point is that the leprosy does not come to mind because 
of the rare occurrence in some areas and the patients are followed up with false diagnoses. 
The implementation of information programs for healthcare professionals is also important 
in this context [114–116].
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